Ora Secures Vistria Group Investment for Global Growth in Ophthalmic Research
Ora, a leading global contract research organization (CRO) specializing in ophthalmic research, has announced a strategic recapitalization by The Vistria Group, a middle-market private investment firm focused on delivering financial…
Novo Integrated Sciences Receives Notice to Commence SBLC Leasing and Monetizing Program
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) announced today the initiation of disbursement for the full monetization of a Standby Letter of Credit (“SBLC”). This initial disbursement marks the first payment…
Opdivo plus Yervoy Application Validated by EMA for Liver Cancer
Bristol Myers Squibb (NYSE: BMY) has announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line…
AscellaHealth’s Q2 2024 Specialty & Rare Pipeline Digest™ Shows Rising Specialty Pharmaceuticals Demand
AscellaHealth, a global partner specializing in end-to-end solutions for life sciences and healthcare companies aimed at improving the quality of life for patients with complex, chronic conditions, has launched its…
Vabysmo by Genentech Demonstrates Long-Term Effectiveness and Safety in Diabetic Macular Edema Study
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), unveiled new four-year findings from the RHONE-X extension study today. The study successfully met all primary endpoints, underscoring…
Lynch Regenerative Medicine Concludes Series A Funding Round
Lynch Regenerative Medicine, LLC (LRM) has successfully concluded its Series A financing to advance innovative skin rejuvenation and regeneration solutions based on FDA-approved pure platelet-derived growth factor (PDGF). Champion VC,…
CytoReason Raises $80M to Expand AI Disease Models, Launch US Hub
CytoReason, a pioneer in computational disease models for predictive insights, has secured $80 million from OurCrowd, NVIDIA (Nasdaq: NVDA), Pfizer (NYSE: PFE), and Thermo Fisher Scientific (NYSE: TMO). “This investment…
MedImpact Successfully Integrates Elixir Solutions
MedImpact Healthcare Systems, Inc., the nation’s largest independent provider of health solutions, technology, and pharmacy benefit management services, has announced the successful completion of the integration of Elixir Solutions. This…
Novocuff secures $26M to advance tech combating preterm births.
Novocuff, Inc., a medical device company focused on enhancing pregnancy outcomes and minimizing the risk of preterm birth, has successfully concluded an oversubscribed $26 million Series A funding round following…
Galvani Bioelectronics Advances Therapy Platform, Appoints New Chief Medical Officer
Galvani Bioelectronics, a clinical-stage therapeutics company resulting from a partnership between GSK and Verily Life Sciences, has initiated recruitment for the randomized, controlled phase of a clinical feasibility study targeting…
Study Finds No Survival Difference Between Mismatched and Matched Unrelated Donors
Research findings published today in the peer-reviewed Journal of Clinical Oncology by NMDP℠ and CIBMTR® (Center for International Blood and Marrow Transplant Research®) indicate that there is no significant difference…
Sensorion Reports Positive Secondary Endpoints in SENS-401 Phase 2a Trial for Hearing Loss Preservation
Sensorion (FR0012596468 – ALSEN), a pioneering biotechnology company specializing in hearing loss disorders, has unveiled new positive findings from its SENS-401 Phase 2a clinical trial. The data, focusing on the…